2017-05-12T11:48:37-07:00 2016-12-31 Lane & Company CPAs 1717 Pennsylvania Avenue NW Suite 4 Washington DC 20006 990 2016-01-01 830397854 KING HUSSEIN CANCER FOUNDATION USA KING 9175920901 601 MASSACHUSETTS AVE NW WASHINGTON DC 20001 LEILA LARIJANI TREASURER 9175920901 2017-05-12 true ROBERT E LANE 2024636500 2017-05-12 X 208.82.213.94 2017-05-12 11:48:30 PD P 08CFD1AD8CBCC6749B8F9123897879BF0476B103 08CFD1AD8CBCC6749B8F9123897879BF0476B103 2016 2021-01-29 14:40:06Z YOLANDA GASALLA 601 MASS AVE NW 7403B WASHINGTON DC 20001 332124 false X WWW.KHCFUSA.ORG X 2004 DC SEE SCHEDULE O. 9 9 0 10 0 880441 332038 0 149 86 0 880590 332124 1337890 222537 0 0 0 0 12678 9589 1350568 232126 -469978 99998 739264 839262 0 739264 839262 SEE SCHEDULE O. false false 222537 222537 THE ORGANIZATION PROVIDED GRANTS FOR CANCER RESEARCH AND TREATMENT AT THE KING HUSSEIN CANCER CENTER IN JORDAN. 222537 true true false false false false false false false false false false false false false false false false false false true true false false false false false false false false false false false false false false false false false false false false false false false false false true 2 0 true 0 false false false false false false false false false false X 9 9 true false false false false false false true true false false true true true true false false false false false X LEILA LARIJANI 9175920901 1285 AVENUE OF THE AMERICAS NEW YORK NY 10019 X YOLANDA GASALLA PRESIDENT 1.00 X X 0 0 0 HRH PRINCESS GHIDA TALAL EXECUTIVE VP 1.00 X X 0 0 0 LEILY BATMANGHELIDJ SECRETARY 1.00 X X 0 0 0 LEILA LARIJANI TREASURER 1.00 X X 0 0 0 DR RONALD DOZORETZ DIRECTOR 1.00 X 0 0 0 ISABEL DE LA CRUZ ERNST DIRECTOR 1.00 X 0 0 0 SAMIA FAROUQI DIRECTOR 1.00 X 0 0 0 HRH PRINCESS DINA MIRED DIRECTOR (UNTIL 6/30/16) 1.00 X 0 0 0 ERIN WALSH DIRECTOR 1.00 X 0 0 0 CLAUDE WASSERSTEIN DIRECTOR 1.00 X 0 0 0 false false false 332038 332038 86 86 332124 86 222537 222537 990 0 990 0 6150 0 6150 0 1205 0 1205 0 REGISTRATION SERVICES 296 0 296 0 LICENSES & FEES 948 0 948 0 232126 222537 9589 0 739264 839262 739264 839262 0 0 X 739264 839262 739264 839262 739264 839262 99998 X false false false X 3386886 771302 1128935 880441 332038 6499602 3386886 771302 1128935 880441 332038 6499602 4815058 1684544 437 80 132 149 86 884 6500486 0.25910 0.24040 X 0 0 0 Pt II Ln 17a THE ORGANIZATION SATISFIES THE FACTS AND CIRCUMSTANCES TEST UNDER REG. SEC. 170-9(f)(3) FOR THE FOLLOWING REASONS: THE ORGANIZATION FACILITATES NUMEROUS FUNDRAISING OPPORTUNITIES IN CONNECTION WITH THE KING HUSSEIN CANCER FOUNDATION (AND ITS CANCER CENTER) THAT THE ORGANIZATION SUPPORTS, INCLUDING OPPORTUNITIES TO RECEIVE ONLINE CONTRIBUTIONS. SINCE ITS INCEPTION, THE ORGANIZATION HAS RECEIVED CONTRIBUTIONS FROM A BROAD BASE OF DONORS THAT INCLUDE HUNDREDS OF INDIVIDUALS, COMPANIES AND OTHER CHARITIES - THE ORGANIZATION HAS RECEIVED TWO LARGE CONTRIBUTIONS, WHICH DO NOT QUALIFY AS "UNUSUAL GRANTS" FROM A FAMILY THAT HAS SUPPORTED THE ORGANIZATION SINCE INCEPTION. THE ORGANIZATION HAS A DIVERSE AND INDEPENDENT GOVERNING BOARD COMPRISED OF INDIVIDUALS WITH RELEVANT EXPERTISE TO THE MISSION AND OPERATIONS OF THE ORGANIZATION, INCLUDING FUNDRAISING, FINANCIAL CONTROLS, AND SUBJECT MATTER EXPERTISE IN CANCER RESEARCH. FINALLY, THE ORGANIZATION'S MISSION IS TO SUPPORT STATE-OF-THE-ART COMPREHENSIVE CANCER CARE, WHICH IS A CHARITABLE PURPOSE WITH A BROAD PUBLIC APPEAL. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true Middle East 0 0 GRANTS TO RECIPIENT GRANT 222537 0 0 0 0 222537 222537 Middle East CANCER TREATMENT 222537 WIRE 1 false false false false false false Pt I Line 2 THE BOARD RECEIVES AND REVIEWS DETAILED REPORTS THAT DESCRIBE THE ACTIVITIES AND EXPENDITURES SUPPORTED BY THE GRANTS. Other PT 1, LINE 1 AND PART III, LINE 1: PRIMARY EXEMPT PURPOSE: TO OPERATE EXCLUSIVELY FOR CHARITABLE, EDUCATIONAL AND CULTURAL PURPOSES. MORE SPECIFICALLY, THE ACTIVITIES OF THE CORPORATION SHALL INCLUDE SUPPORTING THE WORK AND FURTHERING THE MISSION OF THE KING HUSSEIN CANCER FOUNDATION IN JORDAN; PROMOTING AND PROVIDING EDUCATIONAL MATERIALS AND INFORMATION ON THE KING HUSSEIN CANCER FOUNDATION USA; SUPPORTING THE ADVANCEMENT OF RESEARCH AND TREATMENT OF CANCER, AND ENGAGING IN FUNDRAISING ACTIVITIES TO SUPPORT THE WORK OF THE CORPORATION. Pt VI, Line 2 HRH PRINCESS GHIDA TALAL AND HRH PRINCESS DINA MIRED ARE RELATED BY MARRIAGE THROUGH THEIR SPOUSES. Pt VI, Line 11b A COPY IS EMAILED TO EACH OF THE BOARD MEMBERS. THE TREASURER REVIEWS THE 990 INDEPENDENTLY WITH THE CORPORATION'S LEGAL COUNSEL. Pt VI, Line 12c THE CORPORATION'S POLICY IS WRITTEN TO PROTECT THE CORPORATION'S INTEREST WHEN IT IS CONTEMPLATING ENTERING INTO A TRANSACTION OR ARRANGEMENT THAT MIGHT BENEFIT THE PRIVATE INTEREST OF THE CORPORATION'S DIRECTORS, OFFICERS, OR COMMITTEE MEMBERS. IN CONNECTION WITH ANY POSSIBLE CONFLICTS OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER INTEREST AND ALL MATERIAL FACTS TO THE DIRECTORS CONSIDERING THE PROPOSED TRANSACTION OR AGREEMENT. AFTER DISCLOSURE OF ALL MATERIAL FACTS AND DISCUSSION WITH THE PERSON, THE PERSON SHALL LEAVE THE BOARD MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD MEMBERS SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. IF THE BOARD MEMBERS FIND THAT A CONFLICT OF INTEREST EXISTS, THE BOARD MEMBERS SHALL DETERMINE WHETHER THE CORPORATION CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR AGREEMENT WITH REASONABLE EFFORTS THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. Pt VI, Line 19 KING HUSSEIN CANCER FOUNDATION USA MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST.